Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.
Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.
One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.
Among patients with short-term peripherally inserted central catheter, about 1 in 10 has a complication
Better reimbursement at hospital outpatient depts, even though drug-level costs lower in doctor's office
Certain chemotherapies might shorten telomeres and alter microRNA.
Decrease in estimated out-of-pocket spending at the 25th, 50th, 75th percentiles; increase at 90th, 95th
Radical cystectomy is associated with better survival, but findings suggest BPT may produce acceptable oncologic outcomes in appropriately selected patients.
Which vaccines should be avoided in patients receiving chemotherapy?
The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.
Just 1 in 4 patients diagnosed with metastatic urothelial carcinoma of the bladder survive for a year, according to US national registry data.
Researchers find prolonged survival among patients with neuroendocrine muscle-invasive bladder cancer.
Five-year cancer-specific survival rates were 48.1% and 69.6% for PD-L1 positive and negative patients, respectively.
The NFB group demonstrated greater improvement than the controls on the Brief Pain Interval program.
Finding contrasts with results of randomized clinical trials.
A patient developed a rare and incurable fungal infection after using aerosolized marijuana and ultimately died.
The proportion of patients receiving neoadjuvant chemotherapy in the United States rose from 0.6% to 2.7% between 2004 and 2013.
Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.
Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.
Severe to profound hearing loss seen in 18% of male germ cell tumor survivors.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.
In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.
A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.
Therapy used in less than 5% of cases, even in those with higher clinical stage.
The guidelines were assessed for developmental rigor, and the ASCO endorsed all but one of the guidelines.
Placebo group had significant hearing loss at one month at both 2,000 HZ and 8,000 HZ.
Improved survival with adjuvant chemotherapy in patients with locally advanced disease compared with cystectomy alone.
Researchers estimate that 40% of pathologic response in MIBC patients receiving both neoadjuvant chemo and TURBT is due to TURBT.
Overall survival and radiographic progression-free survival trends demonstrate treatment benefit of abiraterone acetate in prostate cancer.
Renal and Urology News Articles
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
- PET/CT May Improve Imaging of Recurrent Prostate Cancer
- Adding MRI Does Not Boost Prostate Cancer Upgrading Rate
- Both High and Low Uric Acid Levels Tied to Higher Mortality
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)